InvestorsHub Logo
Followers 7
Posts 141
Boards Moderated 0
Alias Born 07/31/2015

Re: JTrader post# 98

Wednesday, 09/14/2016 10:43:19 PM

Wednesday, September 14, 2016 10:43:19 PM

Post# of 138
Would recommend everyone listen to their after hours conference call today. Analysts on the call sounded really impressed as was I. Company and partner reps on the call could barely tame their enthusiasm

There is big WOW factor in their data - very early, just 7 patients through 90 days. But they have already met their 12 month study goals in less than 90 days. This with lower dosages than they are now approved to give (20 million cells versus 2 and 10 million in early 7 patient group).

The data should only get better with them now looking into partial spine fracture patients and not just total fractures (first 7 patients). This is a platform drug offering that may address other unmet needs and management has a history of delivering big.

Check out slide 10 on the link below. The UEMS scores at DAY 90 range from (0-50) where a score of 50 represents full upper body motor recovery (I had to listen to the ear popping conference call after hours tonight to get that answer). They are seeing early patients scores surge to around/above 40 (50 is max) in less than 90 days. This is far better and far earlier than even their previous hopeful high expectations based on early trial data (mainly in animals). It works!!!